Bristol-Myers Squibb announced that the U.S. FDA has approved use of Yervoy (ipilimumab) as an adjuvant therapy (a therapy that enhances initial treatment) for high-risk patients with Stage III melanoma, to lower the risk that the disease will recur or advance after lymph node surgery.  Ipilimumab was approved in 2011 only for patients with Stage IV melanoma; the hope is that it will now have even greater benefits for patients whose disease is less advanced, preventing or delaying disease recurrence and progression.  Resectable, Stage III melanoma represents 5 percent, or approximately 3,100 cases, of all new melanoma cases diagnosed annually. This stage of melanoma can be aggressive, with a 60 percent risk of recurrence after surgery.